Abstract As part of its single technology appraisal (STA) process, the National Institute for Health and Care Excellence (NICE) invited the manufacturer of vedolizumab (Takeda UK) to submit evidence of the clinical effectiveness and cost effectiveness of vedolizumab for the treatment of patients with moderate-to-severe active ulcerative colitis (UC). The Evidence Review Group (ERG) produced a critical review of the evidence for the clinical effectiveness and cost effectiveness of the technology, based upon the company's submission to NICE. The evidence was derived mainly from GEMINI 1, a Phase 3, multicentre, randomised, double-blinded, placebo-controlled study of the induction and maintenance of clinical response and remission by vedolizumab (MLN0002) in patients with moderate-to-severe active UC with an inadequate response to, loss of response to or intolerance of conventional therapy or anti-tumour necrosis factor (TNF)-a. The clinical evidence showed that vedolizumab performed significantly better than placebo in both the induction and maintenance phases. In the post hoc subgroup analyses in patients with or without prior anti-TNF-a therapy, vedolizumab performed better then placebo (p value not reported). In addition, a greater improvement in health-related quality of life was observed in patients treated with vedolizumab, and the frequency and types of adverse events were similar in the vedolizumab and placebo groups, but the evidence was limited to short-term follow-up. There were a number of limitations and uncertainties in the clinical evidence base, which warrants caution in its interpretation-in particular, the post hoc subgroup analyses and high dropout rates in the maintenance phase of GEMINI 1. The company also presented a network metaanalysis of vedolizumab versus other biologic therapies indicated for moderate-to-severe UC. However, the ERG considered that the results presented may have underestimated the uncertainty in treatment effects, since fixed-effects models were used, despite clear evidence of heterogeneity among the trials included in the network. Results from the company's economic evaluation (which included price reductions to reflect the proposed patient access scheme for vedolizumab) suggested that vedolizumab is the most effective option compared with surgery and conventional therapy in the following three populations: (1) a mixed intention-to-treat population, including patients who have previously received anti-TNF-a therapy and those who are anti-TNF-a naïve; (2) patients who are anti-TNF-a naïve only; and (3) patients who have previously failed anti-TNF-a therapy only. The ERG concluded that the results of the company's economic evaluation could not be considered robust, because of errors in model implementation, omission of relevant comparators, deviations from the NICE reference case and questionable model assumptions. The ERG amended the company's model and demonstrated that vedolizumab is expected to be dominated by surgery in all three populations.
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Introduction
Health technologies must be shown to be clinically effective and to represent a cost-effective use of National Health Service (NHS) resources in order to be recommended for use within the NHS in England and Wales. The National Institute for Health and Care Excellence (NICE) is an independent organisation responsible for providing national guidance on promoting good health and preventing and treating ill health in priority areas with a significant impact. The NICE single technology appraisal (STA) process usually covers new technologies within a single indication, soon after they have received UK marketing authorisation [1] . Within the STA process, the company provides NICE with a written submission that summarises the company's estimates of the clinical effectiveness and cost effectiveness of the technology, together with an executable health economic model. This submission is reviewed by an external organisation independent of NICE, the Evidence Review Group (ERG), which consults with clinical specialists and produces an ERG report. After consideration of the company's submission, the ERG report and testimony from experts and other stakeholders, the NICE Appraisal Committee formulates the preliminary guidance, the Appraisal Consultation Document (ACD), which indicates the initial decision on whether or not to recommend the intervention. Stakeholders are then invited to comment on the submitted evidence and the ACD, after which a subsequent ACD may be produced or a Final Appraisal Determination (FAD) is issued, which is open to appeal. An ACD is not produced when the intervention is recommended without restriction; in that instance, an FAD is produced directly.
This paper presents a summary of the ERG report [2] for the STA of vedolizumab for the treatment of adults with moderate-to-severe active ulcerative colitis (UC) and the subsequent development of the NICE guidance for the use of this drug in England and Wales. Full details of all relevant appraisal documents can be found on the NICE website [3] .
The Decision Problem
UC is a relapsing-remitting form of inflammatory bowel disease (IBD) [4] , with inflammation typically occurring in the colon and rectum. Symptoms include development of bloody diarrhoea with or without mucus, abdominal pain, weight loss, fatigue, rectal urgency and tenesmus [5] [6] [7] . The onset of symptoms and diagnosis of UC usually occur in young-middle aged working adults. The peak incidence is between 15 and 25 years of age, with a potential second peak between 55 and 65 years of age [8] . Over two thirds of patients describe interference with work, and three quarters describe interference with leisure activities [9] . The unpredictable nature of relapse in UC and the significant symptom burden also have a negative effect on patients' psychological well-being and quality of life [10] . UC is recognised as the most common form of IBD in the UK. The incidence of UC is approximately 10 per 100,000 population per year, while the prevalence of the disease is approximately 240 per 100,000 population [8] . The majority (approximately 80 %) of incident cases are reported to be of mild or moderate severity. An estimated 132,600 people in England and Wales have been diagnosed with UC [8] .
Current Treatment
At present, there is no agreed pathway for the management of patients with treatment-refractory (to second-line conventional therapy) moderate-to-severe active UC. The main aim of treatment is to resolve symptoms and maintain remission. Conventional therapy for UC may include aminosalicylates (mesalamine, sulfasalazine, balsalazide or olsalazine), corticosteroids (beclomethasone or prednisolone), thiopurines (mercaptopurine or azathioprine) and calcineurin inhibitors. Tumour necrosis factor (TNF)-a inhibitors (infliximab, adalimumab and golimumab) may be used for disease refractory to conventional therapy [8] . The choice of treatment may be influenced by the severity of symptoms, the extent and the location of inflammation, and is based on clinical expertise and individual patient choice. Patients who fail both conventional and TNF-a inhibitor therapy typically have no other medical therapeutic options available to them, and up to 40 % [11] may progress to surgery [12] . However, people may be reluctant to consider surgery, because of potential serious post-surgery complications such as bleeding, faecal incontinence, depression, distorted body image, sexual dysfunction, female infertility, pouchitis, pouch leakage, pelvic abscesses, pouch fistulae, small bowel obstruction and anastomotic stricture [13] . Current treatment options are also associated with safety concerns associated with long-term use of corticosteroids, immunomodulators and TNF-a inhibitors, including immunosuppression, osteoporosis and lymphoma [14, 15] . Vedolizumab (Entyvio Ò ; Takeda UK) is a humanised monoclonal antibody. It targets a4b7 integrin, which is expressed in certain white blood cells found in the gut. a4b7 integrin is responsible for recruiting these cells to inflamed bowel tissue. Vedolizumab therefore offers gutselective targeted therapy without systemic immunosuppression. On 22 May 2014, the European Medicines Agency (EMA) [16] granted marketing authorisation for the medicinal product Entyvio Ò ''for the treatment of adult patients with moderate-to-severe active UC who have had an inadequate response with, or lost response to, or were intolerant to either conventional therapy or a TNF-a inhibitor. The recommended dosage of vedolizumab is 300 mg given by intravenous infusion at 0, 2 and 6 weeks and then every 8 weeks thereafter. Continued therapy for people with UC should be carefully reconsidered if no evidence of therapeutic benefit is observed by week 10. Some patients with decreased response may benefit from an increase in dosing frequency to 300 mg every 4 weeks.'' NICE issued a final scope [17] in June 2014 to appraise the clinical effectiveness and cost effectiveness of vedolizumab within its licensed indication for the treatment of moderate-to-severe active UC in adults with an inadequate response to, loss of response to or intolerance of conventional therapy or a TNF-a inhibitor.
Independent ERG Review
The company (Takeda UK) provided a submission to NICE on the clinical and cost effectiveness of vedolizumab for the treatment of patients with moderate-to-severe active UC [3, 18] . The ERG critically reviewed the evidence presented in the company's submission by assessing (1) whether the submission conformed to NICE methodological guidelines; (2) whether the company's interpretation and analysis of the evidence were appropriate; and (3) the presence of other evidence or alternative interpretations of the evidence. In addition, the ERG identified areas requiring clarification, for which the company provided additional evidence.
Clinical Effectiveness Evidence Submitted by the Company
The company's submission [3, 18] [19] , which forms the main supporting evidence for the intervention, was a Phase 3, multicentre, randomised, double-blinded, placebo-controlled trial, performed in 34 countries (including two sites in the UK), to evaluate the efficacy and safety of vedolizumab (MLN0002) as an induction treatment (in weeks 0-6) and maintenance treatment (in weeks 7-52) in patients with moderate-tosevere active UC with an inadequate response to, loss of response to or intolerance of conventional therapy or a TNF-a inhibitor. In the 6-week induction phase, 374 patients were randomised (in a 3:2 ratio) to receive vedolizumab 300 mg intravenously or placebo (as saline) in weeks 0 and 2, with two stratification factors: (1) concomitant use or non-use of glucocorticoids; and (2) concomitant use or non-use of immunosuppressive agents or prior use or non-use of anti-TNF-a agents. In order to fulfil sample size requirements for the maintenance study, an additional 521 patients were enrolled in an open-label group, who received the same treatment regime. The primary end point was clinical response at week 6 (defined as a reduction in the Mayo Clinic score of at least three points and a decrease of at least 30 % from the baseline score, with a decrease of at least one point on the rectal bleeding subscale or an absolute rectal bleeding score of B1). In the double-blinded cohort, patients treated with vedolizumab had significantly higher rates of clinical response, clinical remission and mucosal healing than those treated with placebo (Table 1) . Additional post hoc subgroup analyses showed that in comparison with placebo, treatment with vedolizumab improved clinical response and remission rates at 6 weeks in patients with no prior anti-TNF-a exposure and, to a lesser extent, in those with prior anti-TNF-a failure (p values were not provided, as the company stated that ''multiple testing adjustments were not made''). A post hoc 'delayed responder' exploratory analysis in patients who failed to demonstrate a clinical response at week 6 in the induction phase found that the percentages of vedolizumab-treated patients achieving a clinical response (using partial Mayo scores) at weeks 10 and 14 were 32 % (102/ 322) and 39 % (126/322), respectively, in comparison with 15 % (12/82) and 21 % (17/82), respectively, of those receiving placebo.
Patients with a clinical response at week 6 from both the blinded and non-blinded cohorts (n = 373) were randomised (in a 1:1:1 ratio) in the maintenance phase to receive double-blind treatment with vedolizumab 300 mg intravenously every 8 weeks (with placebo administered every other visit to preserve blinding), vedolizumab 300 mg intravenously every 4 weeks or placebo every 4 weeks for up to 52 weeks. The primary end point was clinical remission at 52 weeks (defined as a Mayo score B2 points with no individual score [1) . According to the company's submission, randomisation was stratified by three factors: (1) cohort; (2) concomitant use or non-use of glucocorticoids; and (3) concomitant use or non-use of immunosuppressive agents or prior use or non-use of anti-TNF-a therapy. Patients in the induction study who did not have a clinical response at week 6 continued to receive their assigned study drug (vedolizumab or placebo) every 4 weeks and were followed through until week 52 separately from the maintenance study.
In the maintenance phase, higher rates of efficacy at week 52 were observed in the vedolizumab (300 mg intravenously) 4-and 8-weekly groups than in the placebo group (Table 2) . No clear differences in efficacy were observed between the two vedolizumab regimens.
Clinical response and remission rates were generally favourable for vedolizumab compared with placebo in both the anti-TNF-a naïve and anti-TNF-a failure subgroups. However, efficacy was greater in the anti-TNF-a naïve group than in the anti-TNF-a failure group (see Table 2 ). In addition, greater health-related quality of life (HRQoL) improvements in both the induction and maintenance phases were observed in patients treated with vedolizumab than in the placebo group.
In general, all efficacy analyses in GEMINI 1 [19] were conducted according to the intention-to-treat (ITT) principle, whereby patients who withdrew prematurely were considered as treatment failures. In the induction phase, 6 % (57/895) of the total population prematurely discontinued from the study. In contrast, a larger proportion of patients discontinued during the maintenance phase [44 % (164/373) of the total population, i.e. responders to vedolizumab during the induction phase who were re-randomised to maintenance therapy at week 6]. The main reasons for discontinuation in the vedolizumab and placebo groups were lack of efficacy or disease-related adverse events (AEs). The frequencies of AEs were similar in the vedolizumab and placebo groups in GEMINI 1 [19] . The most commonly occurring AEs during the maintenance phase in the combined vedolizumab group versus the combined placebo group were nasopharyngitis (12.9 versus 9.5 %), headache (12.9 versus 10.2 %), arthralgia (9.0 versus 9.1 %) and upper respiratory tract infections (8.4 versus 7.6 %). The majority of infusion-related reactions in the induction and maintenance phases were mild to moderate in severity, with only three cases resulting in drug discontinuation. Although no cases of anaphylaxis, serum sickness or progressive multifocal leukoencephalopathy (PML) were observed, one patient died during GEMINI 1 [19] ; this was considered by the study investigators to be unrelated to the treatment. Supplementary safety evidence from an ongoing GEMINI long-term safety (LTS) study [20, 21] (ClinicalTrials.gov identifier NCT00619489) and two separate pooled safety analyses (not meta-analysed) were also provided by the company [22, 23] . In general, the overall safety profile of vedolizumab appeared to be similar in patients with UC and Crohn's disease (CD), with slightly higher rates of AEs in the CD patients. As of June 2013, no cases of PML had been reported in any of the [2700 patients treated with vedolizumab, including approximately 900 patients with C24 months of exposure. In addition, a total of 26 vedolizumab-treated patients in the integrated safety population had been diagnosed with malignancy, of whom 18 met serious AE (SAE) criteria. Tuberculosis (TB) was reported in a total of four patients (three with CD and one with UC), and 13 deaths occurred across all controlled and uncontrolled studies in UC (n = 4) and CD (n = 9). None of the UC deaths were considered by the study investigators to be treatment related.
In the absence of any direct head-to-head randomised controlled trials comparing vedolizumab and other relevant biologic therapies for the treatment of moderate-to-severe UC, the company conducted an NMA. The NMA compared vedolizumab, adalimumab, golimumab, infliximab and placebo for the outcomes of clinical response, durable clinical response, clinical remission, mucosal healing, discontinuation due to AEs, SAEs and corticosteroid-free (CSF) remission, using data from the following trials: GEMINI 1 (vedolizumab) [19] , ULTRA 1 (Ulcerative Colitis Long-Term Remission and Maintenance with Adalimumab) (adalimumab) [24] , ULTRA 2 (adalimumab) [25] , ACT 1 (Active Ulcerative Colitis Trial) (infliximab) [26] , ACT 2 (infliximab) [26] , PURSUIT-SC (Program of Ulcerative Colitis Research Studies Utilizing an Investigational Treatment) (golimumab) [27] , PUR-SUIT-M (golimumab) [28] and Suzuki et al. (adalimumab) [29] . The size of the network for each outcome varied depending on the availability of the data in each study.
The fixed-effects NMA suggested that in the induction phase for anti-TNF-a naïve patients, infliximab provided the largest treatment effect on clinical response, remission and mucosal healing (in comparison with placebo), and vedolizumab was associated with the lowest rate of discontinuations due to AEs (in comparison with placebo). In the induction phase for patients who had previously received TNF-a inhibitors, only the treatment effects of adalimumab and vedolizumab were analysed relative to placebo. Each had positive effects in terms of clinical response, remission and mucosal healing, but only the effect of vedolizumab (compared with placebo) for the outcome of response was statistically significant. For the maintenance phase, vedolizumab was associated with the largest treatment effect (compared with placebo) in both the anti-TNF-a naïve and anti-TNF-a failure patient subgroups. However, only those patients who responded to vedolizumab in the induction phase entered the GEMINI 1 [19] maintenance phase; hence, there were no data available to compare the effect/efficacy of vedolizumab against placebo in the maintenance phase in patients who responded to placebo in the induction phase.
Critique of Clinical Effectiveness Evidence and Interpretation
The systematic review process followed by the company was comprehensive. Despite minor limitations in the company's search strategy, the ERG was confident that all relevant studies of vedolizumab were included in the company's submission. The specified inclusion and exclusion criteria appeared generally appropriate and reflected the information given in the decision problem. The validity assessment tool used to appraise the included studies, as suggested by NICE [30] , was based on the quality assessment criteria for randomised controlled trials and was considered appropriate by the ERG. Although the efficacy and safety of vedolizumab were positively demonstrated (in comparison with placebo) in GEMINI 1 [19] , there were a number of limitations and uncertainties, which warrant caution in the interpretation of the available evidence. Owing to the high discontinuation rates in the maintenance phase of GEMINI 1 [19] , estimates of treatment effects (including magnitude) may have been confounded. The subgroup analyses undertaken to determine the efficacy of vedolizumab in patients with anti-TNF-a failure and in patients who were anti-TNF-a naïve were exploratory, and the study was not powered for these assessments. The duration of treatment with vedolizumab in GEMINI 1 [19] was 52 weeks, followed by enrolment in the ongoing GEMINI LTS study [20, 21] . As a result, the long-term efficacy and safety of vedolizumab are unknown, and the optimum duration of therapy remains unclear. There are no data on strategies for withdrawal of the drug in patients on maintenance therapy or for prediction of instances in which this can be successfully achieved. Furthermore, the safety and efficacy of vedolizumab have not been established in children aged \17 years, pregnant women, women of childbearing potential, lactating mothers, or patients with renal or hepatic impairment, or in concomitant use with biologic immunosuppressants. Finally, of the 211 study sites from which patients were recruited, only two were UK based and 63 were US based. With the exception of the US sites, where permitted immunosuppressants were discontinued after induction, all other sites maintained immunosuppressants at stable doses throughout the induction and maintenance periods. As such, there is some uncertainty regarding the generalisability of the evidence to the clinical population of England and Wales.
Despite considerable differences between the trials included in the company's NMA, the NMA used a fixedeffects model. As a result, the ERG believes that the results presented may have underestimated the uncertainty in treatment effects. Moreover, the main differences between the studies in both the induction phase and the maintenance phase related to the following: patient characteristics, study design (randomisation at baseline or re-randomisation of biologic induction responders) and study duration. Only GEMINI 1 [19] and ULTRA 2 [25] included patients with prior anti-TNF-a experience and anti-TNF-a naïve patients, while ACT 1 [26] , ACT 2 [26] , PURSUIT-SC [27] , Suzuki et al. [29] and ULTRA 1 [24] included only patients who were anti-TNF-a naïve. Within PURSUIT-M [28] , all recruited patients were golimumab induction responders [27] . It is worth noting that patients with prior anti-TNF-a experience may be a more difficult population to treat than those who are anti-TNF-a naïve. Furthermore, the inclusion criteria of GEMINI 1 [19] and ULTRA 2 [25] differed. In GEMINI 1 [19] , failure of anti-TNFs was defined as inadequate response (i.e. primary non-response to induction therapy with anti-TNF therapy), loss of response (i.e. secondary non-response/loss of response to anti-TNFs over time, following an initial response) or intolerance of anti-TNFs. In contrast, ULTRA 2 [25] included people whose disease had lost response to an anti-TNF, or who could not tolerate another anti-TNF, prior to commencement of adalimumab therapy (i.e. this study did not appear to have included primary non-responders to anti-TNFs). In terms of study design, the adjustments made by the company in the maintenance phase of the trials without re-randomisation at the end of the induction phase inflated the estimates of treatment effects in both the placebo and experimental treatment groups. The impact of this adjustment on the relative treatment effects in these trials was not clear. It was also unclear if the large relative treatment effect observed for vedolizumab compared with placebo in the GEMINI 1 [19] maintenance phase was due to the low event rates for placebo, which included only prior vedolizumab induction responders. In contrast, the placebo arm in the ULTRA 2 [25] maintenance phase included both induction responders and non-responders, as patients were randomised to induction and maintenance regimes at baseline. Hence, it was not clear if the placebo groups in these two trials [19, 25] were comparable in the NMA for the anti-TNF-a failure/experience subgroup. The anti-TNF-a naïve subgroup also had this comparability issue in the maintenance phase. The results of the NMA for clinical response and remission should be interpreted with further caution because these were estimated without consideration of the dependence/correlation between response and remission, i.e. remission is a subset of response, and the data are ordered as categorical in nature, but the NMA was binary and considered only response or no response, or remission or no remission. Use of these results in the economic model ignores this dependence and may generate inappropriate samples for probabilistic sensitivity analysis (PSA).
Cost-Effectiveness Evidence Submitted by the Company
The company submitted a model-based cost-utility analysis as part of its submission [3, 18] . The analysis was undertaken from the perspective of the NHS over a 10-year time horizon. The company's analysis was presented for three populations: (1) the mixed ITT population, which comprised patients who had previously received anti-TNFa therapy and those who were anti-TNF-a naïve; (2) patients who were anti-TNF-a naïve only; and (3) patients who had previously failed anti-TNF-a therapy only. Within all three analyses, comparators included conventional nonbiologic therapies (a combination of 5-aminosalicylic acids, immunomodulators and corticosteroids) and surgery as separate options. Other anti-TNF-a agents (infliximab, adalimumab and golimumab) were included only in the analysis of the anti-TNF-a naïve population. Calcineurin inhibitors (tacrolimus and cyclosporin) were not included in the economic analysis. All analyses included price reductions to reflect the proposed patient access scheme (PAS) for vedolizumab. The company's model adopted a hybrid approach whereby a decision tree was used to evaluate outcomes at the end of induction therapy and a Markov structure was used to evaluate subsequent maintenance treatment outcomes (including subsequent induction treatment using conventional therapies for patients who discontinue biologic treatments). Pre-colectomy health states were defined according to the Mayo score (remission, mild, moderate-to-severe UC); additional states were included to reflect surgery, post-surgical complications and post-surgical remission and death. The company's results were presented as pairwise comparisons of vedolizumab versus each comparator and were thus difficult to interpret appropriately. On the basis of a fully incremental analysis of all treatment options undertaken by the ERG (see Table 3 ), within the mixed ITT population, the company's model suggests that surgery is dominated, as it produces fewer health gains and is more costly than both conventional therapy and vedolizumab. Vedolizumab is expected to be the most effective option. Compared with conventional therapy, vedolizumab is expected to produce an additional 0.15 quality-adjusted life-years (QALYs) at an incremental cost of £5131; the incremental cost-effectiveness ratio (ICER) for vedolizumab versus conventional therapy is estimated to be £33,297 per QALY gained. Within the anti-TNF-a naïve population, surgery is expected to be dominated by medical therapies. Vedolizumab is expected to be the most effective option. Infliximab and golimumab are expected to be dominated by vedolizumab. The ICER for adalimumab versus conventional therapy is estimated to be £3664 per QALY gained, while the ICER for vedolizumab versus adalimumab is estimated to be £6634 per QALY gained.
Within the anti-TNF-a failure population, surgery is expected to be dominated. Vedolizumab is expected to be the most effective option. Compared with conventional therapy, vedolizumab is expected to produce an additional 0.09 QALYs at an incremental cost of £5839; the ICER for vedolizumab versus conventional therapy is estimated to be £64,999 per QALY gained.
Critique of Cost-Effectiveness Evidence and Interpretation
The ERG critically appraised the company's health economic analysis and the model upon which this analysis was based.
The ERG partially re-built part of the model to check for technical programming errors. One serious programming error was found in the anti-TNF-a naïve population, the maintenance transition matrix for conventional therapy incorrectly drew on the transition matrix for infliximab. Fixing this error, however, did not have a significant impact on the results. The broader critical appraisal of the company's model highlighted a number of concerns and uncertainties. The most notable of these related to (1) the deviations from the NICE reference case [31] and the final NICE scope [17] ; (2) questionable assumptions regarding continuation/discontinuation of vedolizumab and other biologic therapies; (3) highly pessimistic assumptions regarding use, costs and benefits of colectomy; and (4) considerable uncertainty regarding the methods used to (1) missing biologic comparators in the mixed ITT population and the anti-TNF-a failure populations; (2) use of a 10-year (rather than lifetime) time horizon; and (3) use of pairwise comparisons rather than a fully incremental analysis. These issues hindered the interpretation of the company's results against the decision problem specified in the NICE scope [17] . While the ERG was able to re-analyse the company's results using a fully incremental framework over a lifetime horizon, it was not possible to address issues surrounding missing comparators.
Questionable Assumptions Regarding Continuation/Discontinuation of Vedolizumab and Other Biologic
Therapies The company's health economic model assumed that all patients who are still receiving anti-TNF-a therapy at 1 year will discontinue and subsequently receive non-biologic therapies, irrespective of whether they are currently responding to treatment. While there is uncertainty with respect to the long-term efficacy of vedolizumab, infliximab, adalimumab and golimumab, as the randomised phases of trials of these therapies adopted a maximum follow-up of 54 weeks, the wording of the marketing authorisations for the biologics does not stipulate if or when responding patients should discontinue therapy [16, [32] [33] [34] [35] . The ERG had concerns that the discontinuation rule adopted in the company's model would not be adhered to in routine practice, as it may not be preferable to patients and clinicians to withdraw biologic therapy when a patient is still obtaining clinical benefit from it.
Pessimistic Assumptions Regarding Use, Costs and
Benefits of Colectomy A number of assumptions used in the calculation of the surgery and post-surgery health states were likely to bias against surgery and towards medical interventions by overestimating the costs and reducing the health gains of surgery. The surgery health state represents a patient undergoing a colectomy and any further routine surgery associated with the procedure. By returning patients to the surgery health state, to reflect that a proportion of patients undergo further unplanned surgeries, the model assumed that these patients undergo a further colectomy and all associated surgeries. In total, the model assumed that a patient would cycle through the surgery health state 4.3 times over a 10-year period and up to 19 times over a lifetime horizon. The model was also likely to have overestimated the rate of post-surgical complications. Data from the literature on rates of complications up to 30 days and up to 6 months following surgery were converted to constant transition probabilities [36, 37] . These may have overestimated the long-term probabilities of complications, as the likelihood of complications decreases as the time from surgery increases [38, 39] . The health utilities used were also likely to bias against surgery, as the utility for post-surgical remission is lower than that for moderate-to-severe UC, indicating that it would be illogical for any patient to opt for surgery.
Uncertainty Surrounding Pre-Colectomy Maintenance Transition Matrices
The method for deriving the pre-colectomy transition matrices adopted by the company was unconventional. The company's model used the Microsoft Excel Solver add-in to determine pre-colectomy transition probabilities (response, remission and active UC) by comparing the model-predicted proportion of patients in remission or response at 1 year against the observed proportion of patients in remission or response at 1 year in GEMINI 1 [19] , or against the predicted proportion based on the manufacturer's NMAs of induction and maintenance therapies (note: the target data points and their derivation depend on the population considered in the analysis). The ERG had concerns that (1) the company's calibration approach discarded the empirical GEMINI 1 trial data [19] , which could have been used to directly estimate transition probabilities; (2) the initial starting matrix of transitions used in the optimisation approach appeared to be largely arbitrary; (3) the constraints imposed in the optimisation approach appeared to be largely arbitrary (for example, no more than 99.5 % of patients remain in remission over each 8-week cycle); (4) fitting seven unknown parameters to two known data points is likely to result in overfitting, and many combinations of transition probabilities could have fitted the two target data points; and (5) the fitting process ignored those patients who achieved a response but had moderate-to-severe disease. This issue could have been better addressed by use of the observed transitions between moderate-to-severe UC, response and remission states, using the individual patient data from GEMINI 1 [19] . The ERG requested but did not receive these data from the company.
Additional Work Undertaken by the ERG
In light of the problems identified during the critical appraisal, the ERG undertook a number of additional analyses to explore the impact of likely biases on the cost effectiveness of vedolizumab. Nine sets of additional analyses were undertaken in each of the three modelled populations. These included correcting the mistake in the maintenance transition matrix for conventional management in the anti-TNF-a naïve population; use of alternative sources of HRQoL values, i.e. using utilities for patients with UC in various health states (remission, response, moderate-to-severe UC and post-surgery), based on data reported by Woehl et al. [40] and Swinburn et al. [39] ; and amending the surgery and post-surgical transition probabilities to better reflect clinical reality, removing assumptions regarding biologic treatment discontinuation, removing assumptions regarding lower use of conventional therapies while patients are also receiving biologics, and improving the cost estimates used in the model to better reflect the costs borne by the NHS. The ERG also produced a preferred base case, which combines most of these additional analyses. The results of these additional analyses did not consistently favour one particular option but indicated that these issues have the propensity to dramatically shift the ICER for vedolizumab versus other therapies in all three populations. The ERG-preferred base case indicated that surgery was likely to dominate all medical treatments in all three populations analysed. However, surgery may not be an acceptable option for all patients. Where surgery is not an acceptable option in the mixed ITT population, the ICER for vedolizumab versus conventional therapy was estimated to be £53,084 per QALY gained. Where surgery was not an acceptable option in the anti-TNF-a naïve population, vedolizumab is expected to be dominated by adalimumab. Where surgery is not an acceptable option in the anti-TNF-a failure population, the ICER for vedolizumab versus conventional therapy was estimated to be £48,205 per QALY gained.
Conclusion of the ERG Report
On the basis of the evidence submitted by the company, the ERG concluded that vedolizumab was clinically more effective than placebo for the treatment of moderate-tosevere active UC in patients with an inadequate response to, loss of response to or intolerance of conventional therapy or TNF-a. However, there are a number of limitations and uncertainties in the evidence base, which warrants caution in its interpretation. In addition, the results presented in the NMA may have underestimated the uncertainty in treatment effects. The ERG believed that robust estimates of the likely cost effectiveness of vedolizumab could not be made on the basis of the original version of the company's economic model. However, on the basis of the ERG's amended version of the company's model, based on a lifetime horizon, including the revised PAS, surgery was more effective and less costly than vedolizumab. In the whole population, the ICER for vedolizumab compared with conventional therapy was £53,084 per QALY gained. In the population who have not had prior treatment with TNF-a inhibitors, vedolizumab is dominated by adalimumab. In the population in whom treatment with a prior TNF-a inhibitor has failed, the ICER for vedolizumab compared with conventional therapy is £48,205 per QALY gained.
Key Methodological Issues
Several methodological issues in the cost-effectiveness evidence and uncertainties in the clinical effectiveness of vedolizumab were highlighted during the appraisal. The subgroup analyses to determine the efficacy of vedolizumab in patients with prior anti-TNF-a failure and in patients who were anti-TNF-a naïve were exploratory, and the study was not powered for these assessments. Furthermore, there are no data on strategies for withdrawal of the drug or the optimum treatment duration, and the trial was not large enough or of sufficient duration to estimate the risk of uncommon AEs.
The ERG considered that the results of the NMA may underestimate the uncertainty in treatment effects, since fixed-effects models were used, and there was clear evidence of heterogeneity among the trials that were included. There are also issues regarding the adjustment of data to account for re-randomisation, which may lead to bias in the model's results.
The health economic model submitted by the company was subject to a number of issues, which limited the credibility of the company's results. These include errors in model implementation, omission of relevant comparators, deviations from the NICE reference case and questionable model assumptions. While the company's economic analysis suggests that the ICER for vedolizumab is below £7000 per QALY gained within the anti-TNF-a naïve population, the ERG-preferred base case indicates that vedolizumab is expected to be dominated by surgery in all three populations.
NICE Guidance
The Appraisal Committee reviewed the data available on the clinical and cost effectiveness of vedolizumab, having considered evidence on the nature of moderateto-severe active UC and the value placed on the benefits of vedolizumab by people with the condition, those who represent them and clinical experts. It also took into account effective use of NHS resources. In November 2014, the Appraisal Committee produced a preliminary recommendation, recorded in the ACD, which stated the following:
Vedolizumab is recommended within its marketing authorisation as an option for treating moderately to severely active UC in adults only if: the person has not had a TNF-a inhibitor or the person has had a TNF-a inhibitor but could not tolerate it and the company provides vedolizumab with the discount agreed in the PAS. However, vedolizumab is not recommended for treating moderately to severely active UC in people who have not had a response to, or have lost response to, treatment with a TNFa inhibitor. People currently having treatment initiated within the NHS with vedolizumab that is not recommended for them by NICE, should be able to continue treatment until they and their NHS clinician consider it appropriate to stop.
In response to the consultation, the company requested NICE to reconsider its preliminary recommendation regarding use of vedolizumab in patients who have failed TNF-a inhibitor therapy. The company submitted supportive evidence detailing the unmet need associated with anti-TNF-a failure and the limited current options (highdose steroids, anti-TNF-a cycling or surgery) available for this patient group, highlighted the clinical evidence from GEMINI 1 [19] and the limitations of the QALY approach in UC, and submitted a revised cost-effectiveness analysis using the ERG/NICE-suggested base case parameters for the analysis of the anti-TNF-a failure population.
Following further consultation, in June 2015, NICE issued its final guidance and recommended the use of vedolizumab within its marketing authorisation as an option for treating moderately to severely active UC in adults with an inadequate response to, loss of response to or intolerance of conventional therapy or TNF-a inhibitor therapy, but only if the company provided vedolizumab with the discount agreed in the PAS. Vedolizumab should be given until it stops working or surgery is needed. At 12 months after the start of treatment, people should be reassessed to see whether treatment should continue. Treatment should continue only if there is clear evidence of ongoing clinical benefit. For people who are in complete remission at 12 months, consideration should be given to stopping vedolizumab therapy. However, if patients relapse, treatment should be resumed. People who continue receiving vedolizumab should be reassessed at least every 12 months to see whether continued treatment is justified [41] .
Consideration of Clinical and Cost-Effectiveness Issues
This section discusses the key issues considered by the Appraisal Committee. The full list can be found in the Appraisal Committee's FAD [41] .
Generalisability to the UK Population
The Committee considered the generalisability of the population in GEMINI 1 to the population who would receive vedolizumab in clinical practice in England. The Committee understood that GEMINI 1 [19] was an international study and two of the centres were in the UK. It was aware that there were differences in the study entry criteria between the USA and other centres. These differences related to which previous treatments had failed and use of immunosuppressants during the study. The Committee heard from clinical experts that the population included in the trial broadly reflected the population who would be treated with vedolizumab in England. It also heard that differences in immunosuppressant use between trial centres were unlikely to affect the trial's generalisability to clinical practice in England. The Committee concluded that the clinical efficacy results from GEMINI 1 [19] were generalisable to clinical practice but that there was uncertainty about whether the proportion of people who had previous TNF-a inhibitor treatment in GEMINI 1 [19] would be the same as that in the population considered for vedolizumab treatment in England.
Estimation of the Size of the Clinical Effectiveness
The Committee discussed the efficacy estimates for vedolizumab from GEMINI 1 [19] . The Committee noted that in GEMINI 1 [19] , people received vedolizumab in weeks 0 and 2 and response was assessed at week 6, but the marketing authorisation for vedolizumab states that people should receive three doses before response is assessed at week 10. The Committee concluded that although the efficacy of vedolizumab had been shown in GEMINI 1 [19] , this may have underestimated the proportion of people who would have a response to induction treatment in clinical practice, and that data on the outcome for those who responded after 6 weeks were not available from the trial.
Uncertainties Generated by the Evidence
The Committee considered the NMA presented by the company to estimate the relative effectiveness of vedolizumab [19] compared with adalimumab [25] , infliximab [26] and golimumab [27] . It noted that clinical data for infliximab [26] and golimumab [27] were not available for people who had previously received a TNF-a inhibitor. Therefore, for this subgroup, a comparison could be made only between vedolizumab [19] and adalimumab [25] . The Committee understood that the company had presented an NMA for the subgroups rather than the whole population. The Committee noted the ERG's concerns that there were differences between the trials included in the meta-analyses and that the company had presented results from a fixedeffects model, which was less suitable than a random-effects model in these circumstances. The Committee understood that an NMA for the whole population would include data from studies that included people who had, and people who had not, taken a TNF-a inhibitor, and that these differences in patient characteristics may affect the results. Therefore, the Committee recognised that the relative effectiveness of vedolizumab compared with TNF-a inhibitors, obtained from a mixed treatment comparison of the whole population, would be subject to considerable uncertainty.
Uncertainties Around Plausibility of Assumptions and Inputs in the Economic Model
The Committee discussed the uncertainty around the cost and frequency of surgery. The Committee noted that when the company's model was run, people would have four operations over 10 years and up to 19 operations over a lifetime time horizon. The ERG considered that the total number of operations, and therefore the costs, were overestimated by the company. The clinical experts highlighted that surgery for UC was normally carried out in three stages in separate operations, and a person could have further surgery if there were complications or further problems. The ERG considered the costs of surgery reported by Buchanan et al. [42] , which were used by the company and represented the total cost of multiple operations. The clinical experts argued that the costs reported by Buchanan et al. [42] accounted for the cost of only one operation. The Committee concluded that the total costs of surgery in the company's base case were too high because of the number of operations included, and that those in the ERG exploratory base case were too low.
Appraisal Committee's Key Conclusion
The Committee considered that taking into account the uncertainty of the utility values, and the costs of surgery and post-surgery care, the ICER of vedolizumab for people who had not had TNF-a inhibitors before was well within the range normally considered to be cost effective. It was concerned that the plausible ICERs for people in whom treatment with a TNF-a inhibitor had failed were around the upper limit of the range normally considered to be a cost-effective use of NHS resources. The Committee recommended vedolizumab within its marketing authorisation as an option for treating moderately to severely active UC in adults only if the company provides vedolizumab with the discount agreed in the PAS.
